TISIDB

Summary
Symbol	FAM101A
Name	family with sequence similarity 101, member A
Aliases	FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location	12q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytoskeleton Note=Colocalizes with FLNA along actin bundle-like structures.
Domain	PF15068 FAM101 family
Function	Involved in the regulation of the perinuclear actin network and nuclear shape through interaction with filamins. Plays an essential role in actin cytoskeleton formation in developing cartilaginous cells.

> Gene Ontology [ TOP ]
Biological Process	GO:0001501 skeletal system development GO:0001503 ossification GO:0002062 chondrocyte differentiation GO:0002063 chondrocyte development GO:0007015 actin filament organization GO:0010721 negative regulation of cell development GO:0021700 developmental maturation GO:0030278 regulation of ossification GO:0030279 negative regulation of ossification GO:0030282 bone mineralization GO:0030500 regulation of bone mineralization GO:0030502 negative regulation of bone mineralization GO:0031214 biomineral tissue development GO:0032330 regulation of chondrocyte differentiation GO:0032331 negative regulation of chondrocyte differentiation GO:0035630 bone mineralization involved in bone maturation GO:0043931 ossification involved in bone maturation GO:0048705 skeletal system morphogenesis GO:0048799 animal organ maturation GO:0051216 cartilage development GO:0060348 bone development GO:0061035 regulation of cartilage development GO:0061037 negative regulation of cartilage development GO:0061181 regulation of chondrocyte development GO:0061182 negative regulation of chondrocyte development GO:0061448 connective tissue development GO:0061572 actin filament bundle organization GO:0070167 regulation of biomineral tissue development GO:0070168 negative regulation of biomineral tissue development GO:0070977 bone maturation GO:0071695 anatomical structure maturation GO:1900157 regulation of bone mineralization involved in bone maturation GO:1900158 negative regulation of bone mineralization involved in bone maturation GO:1903010 regulation of bone development GO:1903011 negative regulation of bone development
Molecular Function	GO:0031005 filamin binding
Cellular Component	GO:0015629 actin cytoskeleton GO:0032432 actin filament bundle

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	FAM101A
Name	family with sequence similarity 101, member A
Aliases	FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location	12q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FAM101A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	FAM101A
Name	family with sequence similarity 101, member A
Aliases	FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location	12q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FAM101A in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FAM101A
Name	family with sequence similarity 101, member A
Aliases	FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location	12q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FAM101A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.775	0.0513
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.472	0.0267
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.252	0.65
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.518	0.324
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.814	0.444
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.152	0.913
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0	1
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0	1
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0	1
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	2.198	0.0335
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.976	0.0272
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0	1

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FAM101A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	FAM101A
Name	family with sequence similarity 101, member A
Aliases	FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location	12q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FAM101A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FAM101A
Name	family with sequence similarity 101, member A
Aliases	FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location	12q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FAM101A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FAM101A. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FAM101A
Name	family with sequence similarity 101, member A
Aliases	FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location	12q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FAM101A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FAM101A
Name	family with sequence similarity 101, member A
Aliases	FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location	12q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FAM101A expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FAM101A
Name	family with sequence similarity 101, member A
Aliases	FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location	12q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FAM101A and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FAM101A
Name	family with sequence similarity 101, member A
Aliases	FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location	12q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FAM101A collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse FAM101A